Timothy Ryan Fong

7671026, Mar 2, 2010

Nov 17, 2003

10/535167

Timothy Fong - Moraga CA, US
Alexis E. Te - Manhasset NY, US

Sangstat Medical Corporation - Fremont CA

A61K 38/08
A61K 38/02

514 15, 514 2

The methods and compositions relate to treatment of disorders of the bladder. In particular, the methods provide for treatment of interstitial cystitis and related disorders. The methods further comprise treatment to affect various manifestations associated with interstitial cystitis, including, reducing histamine release, modulating Substance P expression, modulating nerve growth factor expression, modulating levels of various cytokines, and maintaining integrity of the urine/blood barrier.

7744900, Jun 29, 2010

Apr 29, 2008

12/111305

John M Polo - Hayward CA, US
Barbara A Belli - San Diego CA, US
Silvia Perri - Castro Valley CA, US
Timothy C Fong - Moraga CA, US

Novartis Vaccines and Diagnostics, Inc. - Emeryville CA

A61K 39/12
C12P 21/02
C12P 15/00
C07H 21/04

4241991, 4353201, 435 6951, 536 2372

Expression cassettes are provided comprising a promoter operably linked to a nucleic acid molecule which, when transcribed in vivo, forms double-stranded RNA that induces the production of interferon. Expression cassettes also are provided comprising a promoter operably linked to a ribozyme or antisense nucleic acid molecule which, when transcribed in vivo, forms a ribozyme or antisense RNA molecule that stimulates an immune response. In addition, expression cassettes are provided comprising a promoter operably linked to a ribozyme or antisense nucleic acid molecule which, when transcribed in vivo, stimulates apoptosis. Finally, gene delivery vectors are provided which contain such expression cassettes, host cells containing the gene delivery vectors, and methods of utilizing the expression cassettes, gene delivery vectors, and host cells.

8252587, Aug 28, 2012

Oct 25, 2005

11/259592

Timothy C. Fong - Moraga CA, US
Adrianus Geertrudis Wilhelmus Domen - Tuscon AZ, US
Julie Lynne Christensen - Boulder Creek CA, US

Celerant Therapeutics, Inc. - San Carlos CA

C12N 5/078

435372, 435325

The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation.

8481315, Jul 9, 2013

Sep 24, 2012

13/625768

Timothy C. Fong - Moraga CA, US
Adrianus Geertrudis Wilhelmus Domen - Tucson AZ, US
Julie Lynne Christensen - Boulder Creek CA, US

Cellerant Therapeutics, Inc. - San Carlos CA

C12N 5/078

435372, 435325

The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation.

20030228298, Dec 11, 2003

Sep 4, 2002

10/233675

Mark Nesbit - Vincennes, FR
Timothy Fong - Moraga CA, US
Dirk Brockstedt - Oakland CA, US

A61K038/43
C12Q001/68
C07H021/04
C12N009/99
C12P021/02
C12N005/06

424/094100, 435/069200, 435/184000, 435/320100, 435/325000, 536/023200, 435/006000

The invention relates to abrogen polypeptides and nucleic acids that encode them. In general, the abrogen polypeptides comprise the kringle domain from, for example, urokinase plasminogen activator. Abrogen polypeptides can be used to inhibit endothelial cell activation and/or proliferation and can inhibit endothelial cells activated or induced by both bFGF and VEGF. The invention also encompasses methods to produce polypeptides that possess abrogen activity as well as method for using these polypeptides.

20040186052, Sep 23, 2004

Oct 24, 2003

10/693331

Suhasini Iyer - San Ramon CA, US
Roland Buelow - Palo Alto CA, US
Mirella Lazarov - Palo Alto CA, US
Timothy Fong - Moraga CA, US

A61K038/17

514/012000

Compositions and methods are provided for inhibiting neuronal cell death and the loss of neuronal contacts resulting from acute and chronic neurological disorders, including neurodegenerative and neuroinflammatory diseases. The subject compositions and methods utilize RDP-58 compositions capable of providing a direct neuroprotective effect on neuronal cells in conjunction with the inhibition of autoimmune and inflammatory processes.

20080003224, Jan 3, 2008

Jan 29, 2007

11/699733

Timothy Fong - Moraga CA, US
Varghese Palath - Fremont CA, US
R. Tesi - Berkeley CA, US
Hoang Tran - Menlo Park CA, US
Irving Weissman - Stanford CA, US

Cellerant Therapeutics, Inc. - San Carlos CA

A61K 39/395
A61K 39/00
A61P 35/00
C07K 16/00
C12N 5/00
C12P 21/08

424139100, 424173100, 435346000, 435375000, 530387100, 530387300

The disclosure relates to antibodies immunoreactive with CD45RA+ hematopoietic tumor cells (HTCs), hybridomas producing such antibodies, and methods of using the antibodies, particularly as therapeutic treatments for conditions or diseases characterized by CD45RA+ HTCs.

20130004468, Jan 3, 2013

Jul 2, 2012

13/540471

Timothy C. Fong - Moraga CA, US
Adrianus Geertrudis Wilhelmus Domen - Tucson AZ, US
Julie Lynne Christensen - Boulder Creek CA, US

Cellerant Therapeutics, Inc. - San Carlos CA

A61K 35/12
C12N 5/0789

424 937, 435325, 435374

The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation.